Mirion Technologies, Inc.
Description
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, South Korea, and Japan. It operates through two segments, Medical and Technologies. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Technologies segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. The company was incorporated in 2005 and is headquartered in Atlanta, Georgia.
About
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 27, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| Apr 28, 2025 | — | — | — | — |
| Feb 11, 2025 | 0.14 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 5 |
| Average estimate | — | 0.09 | — | 0.49 |
| Low estimate | — | 0.07 | — | 0.43 |
| High estimate | — | 0.11 | — | 0.63 |
| Last year EPS | — | 0.06 | — | 0.39 |
Growth estimates
Income statement
| 2023 | 2022 | 2020 | 2019 | |
|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 800.90M | 717.80M | — | — |
| Cost of revenue | 444.50M | 407.70M | — | — |
| Gross profit | 356.40M | 310.10M | — | — |
| Operating expense | ||||
| Research & development | 31.70M | 30.30M | — | — |
| Selling general and admin | 340.10M | 362.30M | 2.45M | 341 |
| Other operating expenses | — | — | — | — |
| Operating income | -15.40M | -82.50M | -2.45M | -341 |
| Non operating interest income | ||||
| Income | 4.80M | 600,000 | — | — |
| Expense | 61.90M | 42.50M | — | — |
| Other income expense | -32.80M | -182.20M | -43.07M | — |
| Pretax income | -105.30M | -306.60M | -45.52M | -341 |
| Tax provision | -6.60M | -18.20M | -265,897 | — |
| Net income | -98.70M | -288.40M | -45.26M | -341 |
| Basic EPS | -0.49 | -1.53 | -0.79 | 0.00 |
| Diluted EPS | -0.49 | -1.53 | -0.79 | 0.00 |
| Basic average shares | 196.37M | 181.15M | 56.99M | 20.13M |
| Diluted average shares | 196.37M | 181.15M | 56.99M | 20.13M |
| EBITDA | 153.00M | 93.00M | 40.62M | -341 |
| Net income from continuing op. | -98.70M | -288.40M | -45.26M | -341 |
| Minority interests | 1.80M | 11.50M | — | — |
| Preferred stock dividends | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2.72B | 2.74B | 3.12B | 751.32M | 5,000 |
| Current assets | |||||
| Cash | — | — | — | 383,246 | 5,000 |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 128.80M | 73.50M | 84.00M | 383,246 | 5,000 |
| Other short term investments | 5.30M | 4.30M | 4.90M | — | — |
| Accounts receivable | 172.30M | 171.20M | 157.40M | — | — |
| Other receivables | 48.70M | 50.00M | 56.30M | — | — |
| Inventory | 144.10M | 143.30M | 123.60M | — | — |
| Prepaid assets | 12.10M | 11.50M | 5.30M | 599,170 | — |
| Restricted cash | 600,000 | 500,000 | 600,000 | — | — |
| Assets held for sale | — | 8.50M | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 17.30M | 13.40M | 15.30M | — | — |
| Non current assets | |||||
| Properties | 123.20M | 120.00M | 118.60M | — | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 61.40M | 54.40M | 43.40M | — | — |
| Construction in progress | 39.30M | 20.90M | 12.20M | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -56.60M | -30.90M | -4.50M | — | — |
| Goodwill | 3.43B | 3.49B | 4.13B | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 538.80M | 650.40M | 806.90M | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 26.20M | 25.30M | 81.70M | 750.33M | — |
| Total liabilities | 1.17B | 1.27B | 1.33B | 99.27M | 636 |
| Current liabilities | |||||
| Accounts payable | 58.70M | 67.70M | 59.40M | 965,370 | 636 |
| Accrued expenses | 18.30M | 18.40M | 19.60M | 375,000 | — |
| Short term debt | 8.00M | 13.80M | 13.20M | — | — |
| Deferred revenue | 111.90M | 91.50M | 83.80M | — | — |
| Tax payable | 16.00M | 14.20M | 10.70M | 57 | — |
| Pensions | 42.10M | 37.90M | 34.30M | — | — |
| Other current liabilities | 10.70M | 800,000 | 68.10M | 71.68M | — |
| Non current liabilities | |||||
| Long term debt | 712.80M | 835.80M | 847.40M | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 84.00M | 116.30M | 161.00M | — | — |
| Derivative product liabilities | 55.30M | 30.50M | 68.10M | — | — |
| Other non current liabilities | 50.70M | 44.60M | 36.50M | — | — |
| Shareholders equity | |||||
| Common stock | — | — | — | 750.00M | 2,012 |
| Retained earnings | -505.40M | -408.50M | -131.60M | -97.95M | -636 |
| Other shareholders equity | -65.30M | -75.70M | -20.70M | — | — |
| Total shareholders equity | 1.55B | 1.47B | 1.78B | 652.05M | 4,364 |
| Additional paid in capital | 2.06B | 1.88B | 1.85B | — | 2,988 |
| Treasury stock | 1.30M | — | — | — | — |
| Minority interest | 65.50M | 69.00M | 90.80M | — | — |
Cash flow statement
| 2023 | 2022 | 2020 | 2019 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -98.70M | -288.40M | -45.26M | -341 |
| Depreciation | 162.80M | 174.50M | — | — |
| Deferred Taxes | -30.90M | -37.20M | — | — |
| Stock-Based Compensation | 21.90M | 31.80M | — | — |
| Other Non-Cash Items | 2.50M | 13.40M | — | — |
| Accounts Receivable | -3.10M | -19.30M | -3,883 | — |
| Accounts Payable | -9.90M | 4.50M | 964,734 | 341 |
| Other Assets & Liabilities | 23.70M | -26.70M | -265,954 | — |
| Operating Cash Flow | 68.30M | -147.40M | -44.56M | — |
| Investing Activities | ||||
| Capital Expenditures | -37.10M | -33.40M | — | — |
| Net Intangibles | — | — | — | — |
| Net Acquisitions | -30.40M | -6.60M | — | — |
| Purchase of Investments | — | — | — | — |
| Sale of Investments | 3.80M | 500,000 | — | — |
| Investing Cash Flow | -64.70M | -39.50M | — | — |
| Financing Activities | ||||
| Long-Term Debt Issuance | — | — | — | — |
| Long-Term Debt Payments | -127.30M | -6.60M | -300,000 | — |
| Other Financing Charges | 900,000 | -400,000 | -15.61M | — |
| Financing Cash Flow | 22.60M | -7.00M | 734.09M | — |
| Other Cash Details | ||||
| End Cash Position | 130.50M | 75.00M | 750.45M | 5,000 |
| Income Tax Paid | — | — | — | — |
| Interest Paid | — | — | — | — |
| Free Cash Flow | 58.10M | 5.20M | -945,351 | — |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Janus Henderson Triton Fund | Sep 30, 2024 | 6,815,216 | 108.16M | 3.02% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 6,349,499 | 100.77M | 2.82% |
| Price (T.Rowe) Small Cap Stock Fund | Sep 30, 2024 | 5,778,227 | 91.70M | 2.56% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 5,602,071 | 88.90M | 2.48% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 5,072,046 | 80.49M | 2.25% |
| Price (T.Rowe) Small-Cap Value Fund | Sep 30, 2024 | 4,379,511 | 69.50M | 1.94% |
| Vanguard Information Technology Index Fund | Nov 30, 2024 | 4,342,948 | 68.92M | 1.93% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 3,437,953 | 54.56M | 1.52% |
| Price (T.Rowe) Institutional Small-Cap Stock Fund | Sep 30, 2024 | 2,850,215 | 45.23M | 1.26% |
| Price (T.Rowe) U.S. Small-Cap Core Equity Trust | Sep 30, 2024 | 2,848,470 | 45.21M | 1.26% |
Article
Article
Article
